RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of “Hold” by Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) have earned an average rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price […]

Leave a Reply

Your email address will not be published.

Previous post Progyny, Inc. (NASDAQ:PGNY) Receives $31.90 Consensus Target Price from Brokerages
Next post Donaldson (NYSE:DCI) Downgraded by StockNews.com to Buy